Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Edoxaban	TA355 - Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism	Specialist initiation - For the treatment and secondary prevention of DVT and/or PE - use in line with NICE and supported by RICaD Anticoagulant Initiation Flowchart for Anticoagulation in Atrial Fibrillation
Eltrombopag tablets	TA293 - Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Eluxadoline (Truberzi®)	TA471 - Eluxadoline for treating irritable bowel syndrome with diarrhoea	To be used in line with NICE TA 471. Specialist initiation, and transfer prescribing to GP using RICaD (in development).
Empagliflozin	TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin (Jardiance®)	TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction
Empaglifozin	TA929 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Empaglifozin	TA942 - Empagliflozin for treating chronic kidney disease
Encorafenib (Braftovi®)	TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Encorafenib with binimetinib	TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entrectinib	TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer TA644 - Entrectinib for treating NTRK fusion-positive solid tumours

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.